https://www.taxtmi.com/caselaws?id=222152 The Supreme Court dismissed the appeals filed by Novartis AG, holding that the beta crystalline form of Imatinib Mesylate did not qualify as an invention under the Patents Act, 1970, and failed the test of Section 3(d). The judgment emphasized the need to maintain a high standard for patentability to prevent the evergreening of patents and ensure access to affordable medicines. en-us Mon, 01 Apr 2013 00:00:00 +0530 Tue, 22 Aug 2017 16:07:00 +0530 TaxTMI RSS Generator https://www.taxtmi.com/caselaws?id=222152 The Supreme Court dismissed the appeals filed by Novartis AG, holding that the beta crystalline form of Imatinib Mesylate did not qualify as an invention under the Patents Act, 1970, and failed the test of Section 3(d). The judgment emphasized the need to maintain a high standard for patentability to prevent the evergreening of patents and ensure access to affordable medicines. Case-Laws Indian Laws Mon, 01 Apr 2013 00:00:00 +0530 https://www.taxtmi.com/caselaws?id=222152